CURRENT TRENDS AND AVAILABILITY OF INJECTABLE THERAPY IN PAKISTAN FOR MANAGEMENT OF DIABETES MELLITUS

Background: Diabetes is a metabolic disorder and is a growing healthcare problem in South Asian countries. The management guidelines provided by American Diabetes Association (ADA) have provided a thorough approach for the use of oral and injectable therapies. Current statistics indicate an increase in premature mortality, which poses a severe danger to global prosperity. Sulphonylureas, biguanides, alpha glucosidase inhibitors and thiazolidinediones are examples of recent generations of drugs that have been created as a result of scientific and technological developments and have a high efficacy in reducing hyperglycemia. Objectives: This communication aims to connote the trends and availability of injectable therapy in lower middle income countries. Methodology: We reviewed a number of studies (published between 2010-2020), a market survey for availability and the Drug Regulatory Authority of Pakistan official website for the registration status of newly registered injectable therapy for managing diabetes mellitus. Results: Novel classes of drugs that have been developed as potential targets for diabetes treatment drugs include Incretin mimics, Amylin analogues, GIP analogues, Peroxisome proliferator-activated receptors, and dipeptidyl peptidase-4 inhibitor. In Pakistan and other parts of the world, getting new insulin products in sufficient quantities has always been demanding. A list of imported insulin and GLP-1 products and their availability in lower middle income countries like Pakistan, India and Bangladesh is made so as to meet international standards. Conclusion: This short communicatiob shows the availability of Injectable therapy for management of diabetes in Pakistan.